Welcome To Nutrify Snips

An oat-rich low-gluten diet for six weeks raised fasting plasma short-chain fatty acids particularly butyrate compared with a rice-rich low-gluten diet in people with elevated cardiometabolic risk. The oat diet did not produce meaningful changes in fecal microbiome composition or inflammatory markers. Source : https://pubmed.ncbi.nlm.nih.gov/42379395/ Read More

Lutein and zeaxanthin carotenoids linked to lower risk of cataracts and age‑related macular degeneration were evaluated in Lutemax 2020, a marigold-derived concentrate enriched with lutein, zeaxanthin and the meso‑isomer. Acute testing in rats found no lethality at 2000 mg/kg. In a 90‑day subchronic study, Wistar rats given 0, 4, 40 or 400 mg/kg/day showed no… Read More

Glucagon-like peptide‑1 receptor agonists (GLP‑1 RAs), widely used for diabetes and obesity, may be linked to gallbladder inflammation and gallstones. Using FDA adverse event reports from 2004–2024, researchers found a consistent safety signal connecting commonly prescribed GLP‑1 drugs with cholecystitis and cholelithiasis. Most cases occurred in women over 45, typically after several months of treatment.… Read More

A review of clinical trials compared two drug classes for weight management: GLP‑1 receptor agonists and SGLT‑2 inhibitors. Both improved weight, blood sugar, and blood pressure versus placebo. GLP‑1 drugs were best at lowering blood sugar and one GLP‑1 stood out for the biggest weight and metabolic gains, but it had higher rates of adverse… Read More

SynbioTech has launched SYNMUE, a clinically studied probiotic ingredient containing Lactiplantibacillus plantarum LP28, designed to address immune aging (immunosenescence) by enhancing the activity of Natural Killer (NK) cells an essential component of the body’s innate immune defense that declines with age. In a 12-week randomized, placebo-controlled clinical trial involving adults aged 50–75 years, daily supplementation… Read More